Kürşad Öneç

Dr. Kürşad Öneç

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KÖKürşad Öneç
Kürşad Öneç
GAGülşah Altun
Gülşah Altun
TSTansu Sav
Tansu Sav
Background/Objectives: Mortality among patients receiving maintenance hemodialysis remains high, and biomarkers that allow early risk stratification are needed. Serum albumin reflects nutritional status and systemic inflammation and has been associated with adverse outcomes; however, its long-term prognostic significance remains incompletely defined. This study examined the association between baseline serum albumin and long-term (up to 10-year) all-cause mortality in a large hemodialysis cohort. Methods: This retrospective cohort study included adult patients undergoing maintenance hemodialysis between 2015 and 2025 at a tertiary nephrology center. Individuals with at least three months of stable dialysis and available baseline serum albumin measurements were included. Patients were categorized into two groups according to baseline serum albumin levels (<3.5 g/dL and ≥3.5 g/dL). The primary outcome was long-term (up to 10-year) all-cause mortality, while secondary outcomes included emergency department visits, hospital admissions, cardiovascular events, and infection-related hospitalizations. Survival was assessed using Kaplan–Meier analysis, and predictors of mortality were evaluated using Cox proportional hazards regression. The median follow-up duration was 54 months (interquartile range: 28–92), with a maximum follow-up of 10 years. Results: A total of 412 patients were analyzed, of whom 40.8% had serum albumin levels < 3.5 g/dL. During follow-up, 233 deaths occurred. Lower albumin levels were associated with significantly higher mortality (76.2% vs. 43.4%, p < 0.001), increased healthcare utilization, and a greater incidence of cardiovascular and infectious complications. In multivariate analysis, albumin < 3.5 g/dL remained an independent predictor of mortality (hazard ratio 1.84, 95% confidence interval 1.42–2.38; p < 0.001). Receiver operating characteristic analysis identified 3.4 g/dL as the optimal cutoff for mortality prediction (area under the curve 0.72). Conclusions: Baseline serum albumin is an independent predictor of long-term (up to 10-year) mortality and adverse clinical outcomes in patients receiving maintenance hemodialysis. Although albumin is not a causal determinant, its association with survival likely reflects underlying nutritional and inflammatory burden. Prospective multicenter studies are warranted to validate albumin-based risk stratification and to evaluate the prognostic value of longitudinal changes in serum albumin over time.

2 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KÖKürşad Öneç
Kürşad Öneç
GAGülşah Altun
Gülşah Altun
ŞAŞeyma Özdemir Aytekin
Şeyma Özdemir Aytekin
FDFatih Davran
Fatih Davran
BÖBirgül Öneç
Birgül Öneç
Background/Objectives: Chronic kidney disease (CKD) is commonly complicated by anemia resulting from impaired erythropoietin (EPO) production, iron dysregulation, and chronic inflammation. Erythroferrone (ERFE) and hepcidin are key regulators of erythropoiesis and iron metabolism, but their interaction in CKD remains incompletely understood. This study aimed to examine the associations among ERFE, hepcidin, EPO, and hemoglobin, and to determine whether these markers independently relate to anemia severity in CKD. Methods: This cross-sectional case–control study included 126 patients with CKD (stages 2–5) and 33 age- and sex-matched healthy controls. Laboratory parameters, including hemoglobin, ferritin, transferrin saturation (TSAT), EPO, ERFE, hepcidin, and renal indices (eGFR, BUN, creatinine), were analyzed. Group differences were assessed using ANOVA or Kruskal–Wallis tests with post hoc analyses, and trends were evaluated using the Jonckheere–Terpstra test. Age- and sex-adjusted correlations and multivariable linear regression identified independent associations with hemoglobin. Results: Patients with CKD were older (61.2 ± 14.8 vs. 33.4 ± 10.7 years, p < 0.001) and had lower hemoglobin (11.8 ± 1.9 vs. 13.5 ± 1.4 g/dL, p < 0.001) and higher ferritin levels (245 (110–470) vs. 105 (40–240) ng/mL, p = 0.002) compared with controls. eGFR declined progressively across CKD stages (median (IQR): 73 (64–86) to 12 (7–17) mL/min/1.73 m2, p-trend < 0.001). ERFE and hepcidin showed increasing trends with advancing CKD (p-trend = 0.031 and 0.047, respectively). Hemoglobin correlated negatively with ERFE (r = −0.40, 95% CI: −0.53 to −0.26, p < 0.001) and positively with eGFR (r = 0.42, 95% CI: 0.28–0.54, p < 0.001). In adjusted regression analysis, ERFE (β = −0.29, 95% CI: −0.41 to −0.18, p < 0.001) and eGFR (β = 0.25, 95% CI: 0.13–0.37, p < 0.001) remained independently associated variables of hemoglobin (adjusted R2 = 0.47). Conclusions: Anemia severity in CKD is independently associated with both renal dysfunction and higher ERFE concentrations, suggesting a disrupted ERFE–hepcidin regulatory balance. These findings provide hypothesis-generating insights into the complex interplay between iron metabolism and erythropoiesis in CKD. Validation in larger, multi-center longitudinal studies that include inflammatory markers is warranted.

26 February 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
NINevin İnce
Nevin İnce
KÖKürşad Öneç
Kürşad Öneç
TSTansu Sav
Tansu Sav
MSMehmet Ali SUNGUR
Mehmet Ali SUNGUR
DMDilek Menemenli̇oğlu
Dilek Menemenli̇oğlu
Background/aim: Hantavirus is a rodent borne zoonosis caused by the members of the virus family Bunyaviridae, genus Hantavirus. In this study, we aimed to determine the role of peripheral blood leukocyte ratio in differential diagnosis of Hantavirus disease. Materials and methods: The medical records of patients at the Duzce University Medical Faculty were examined retrospectively. A total of 20 patients diagnosed with hantavirus infection confirmed by serologic tests were included in the study (Group 1). The other group consisted of 30 patients suspected of hantavirus infection but found negative (Group 2). Demographic, clinical and laboratory characteristics, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte (LMR) ratios of both groups were compared. Results: As a result of the istatistics analysis, no difference was found between the groups' age, sex, and clinical complaints except lethargy-weakness (P = 0.004) and diarrhea (P < 0.001). Hemogram analysis showed a significant difference between the groups in terms of leukocyte, hemoglobin, hematocrit, platelet, mean platelet volume (P < 0.05) and PLR (P = 0.001) and LMR (P = 0.003) values from peripheral blood leukocyte ratios. Conclusion: In conclusion, NLR, PLR, and LMR ratios may be useful for clinicians in differential diagnosis of Hantavirus in patients presenting with similar symptoms of Hantavirus disease.

6 June 2020 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
AÖAttila Önmez
Attila Önmez
MAMerve Alpay
Merve Alpay
STSerkan Torun
Serkan Torun
IŞİ. Ethem Şahin
İ. Ethem Şahin
KÖKürşad Öneç
Kürşad Öneç
YDYildiz Degirmenci
Yildiz Degirmenci

17 November 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
KÖKürşad Öneç
Kürşad Öneç
GAGülşah Altun
Gülşah Altun
TSTansu Sav
Tansu Sav
Background/Objectives: Acute kidney injury (AKI) is a common complication in hospitalized patients and carries a substantial risk of chronic kidney disease (CKD), dialysis dependence, and mortality. Although novel biomarkers such as NGAL, KIM-1, and cystatin C have shown promise, their high cost and limited availability restrict their use in routine practice, particularly in developing countries where CKD incidence is rising. The trajectory of serum creatinine decline after its peak may provide a simple, low-cost, and universally available prognostic marker for renal recovery. Methods: This retrospective cohort study included 817 adult patients diagnosed with AKI between January 2015 and December 2024. The creatinine decline rate was calculated as the difference between peak and discharge creatinine divided by hospital stay (mg/dL/day). Patients were stratified into rapid or slow decline groups according to the median value (0.19 mg/dL/day). Post-discharge outcomes, including CKD development, readmission, dialysis requirement, and mortality, were evaluated at 3, 6, and 12 months. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cutoff for predicting renal recovery. Results: Patients in the rapid decline group (n = 409) were younger and had fewer comorbidities and shorter hospital stays than those in the slow decline group (n = 408). The ROC analysis yielded an AUC of 0.78 (95% CI 0.73–0.82, p < 0.001) with an optimal cutoff of 0.18 mg/dL/day (sensitivity 76%, specificity 71%). At 12 months, CKD (18.6% vs. 34.3%), dialysis requirement (3.4% vs. 8.8%), readmission (29.8% vs. 41.2%), and mortality (9.3% vs. 14.2%) were all significantly higher in the slow decline group (all p < 0.05). In multivariable analysis, faster creatinine decline independently predicted renal recovery (OR = 1.36 per 0.1 mg/dL/day, 95% CI 1.22–1.53, p < 0.001), along with younger age, higher serum albumin, and shorter hospital stay. In the longitudinal GEE model, both time (p = 0.004) and group effects (p < 0.001) remained significant, with an interaction effect (p = 0.018) indicating greater eGFR improvement over time among patients with rapid creatinine decline. Conclusions: The rate of creatinine decline is an independent predictor of long-term renal recovery following AKI. This simple and inexpensive parameter may complement novel biomarkers and serve as a practical risk-stratification tool in diverse clinical settings, especially where resources are limited. Prospective multicenter studies integrating albuminuria and emerging biomarkers are warranted to validate and expand these findings.

1 January 2011 in Southern Medical Journal
Verified
Journal Article
Closed access
SISalih Inal
Salih Inal
YEYasemin Erten
Yasemin Erten
KÖKürşad Öneç
Kürşad Öneç
FEFatma Ayerden Ebinç
Fatma Ayerden Ebinç
TATurgay Arinsoy
Turgay Arinsoy
To the Editor: Renal transplantation is the first choice of replacement therapy in patients with end-stage renal disease. New immunosuppressive regimens have greatly reduced the risk of acute rejection and led to overall improvements in graft and patient survival. However, immunosuppressive drugs have numerous side effects and immunosuppression cannot prevent chronic rejection in most cases,...